{"filing":{"accession_number":"0001683168-26-006742","cik":"0001787740","ticker":"VBIO","company_name":"Valion Bio, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-26","primary_document":"valion_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826006742/valion_8k.htm"},"events":[{"id":29927,"run_id":27425,"accession_number":"0001683168-26-006742","anchor_item_number":"3.03","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.9,"summary":"Valion Bio implemented a 1-for-25 reverse stock split effective August 31, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a non-compliance notice on March 19, 2026. The company has until September 15, 2026, to cure the deficiency or face potential delisting from the Nasdaq Capital Market.","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32368,"accession_number":"0001683168-26-006742","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a 1-for-25 reverse stock split undertaken specifically to address a Nasdaq minimum bid price compliance failure. The company received a notification on March 19, 2026, that its stock price fell below $1.00 for 30 consecutive trading days, triggering a 180-day cure period ending September 15, 2026. The reverse split is explicitly described as a measure \"to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" This is a material delisting risk event, as the company faces potential delisting if the reverse split fails to restore compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:46.536235+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32369,"accession_number":"0001683168-26-006742","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"Valion Bio disclosed a 1-for-25 reverse stock split effective August 31, 2026, undertaken specifically to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). The company received a non-compliance notice on March 19, 2026, and was given 180 calendar days (until September 15, 2026) to cure the deficiency. The filing explicitly states the reverse split is intended to \"regain compliance with the Minimum Bid Price Requirement\" and \"enable the Company to maintain its Nasdaq listing,\" indicating material delisting risk if the remedy fails.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:46.536235+00:00","company_name":"","ticker":null,"filing_date":""},{"id":32370,"accession_number":"0001683168-26-006742","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"Valion Bio announced a 1-for-25 reverse stock split effective August 31, 2026, explicitly to \"bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" The company received a Nasdaq notification on March 19, 2026, that its stock price fell below $1.00 for 30 consecutive trading days, triggering a 180-day compliance period ending September 15, 2026. The reverse split directly addresses delisting risk and is material to investors assessing the company's continued exchange listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:46.536235+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32368,"accession_number":"0001683168-26-006742","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a 1-for-25 reverse stock split undertaken specifically to address a Nasdaq minimum bid price compliance failure. The company received a notification on March 19, 2026, that its stock price fell below $1.00 for 30 consecutive trading days, triggering a 180-day cure period ending September 15, 2026. The reverse split is explicitly described as a measure \"to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" This is a material delisting risk event, as the company faces potential delisting if the reverse split fails to restore compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:46.536235+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-08-27"},{"id":32369,"accession_number":"0001683168-26-006742","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"Valion Bio disclosed a 1-for-25 reverse stock split effective August 31, 2026, undertaken specifically to regain compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)). The company received a non-compliance notice on March 19, 2026, and was given 180 calendar days (until September 15, 2026) to cure the deficiency. The filing explicitly states the reverse split is intended to \"regain compliance with the Minimum Bid Price Requirement\" and \"enable the Company to maintain its Nasdaq listing,\" indicating material delisting risk if the remedy fails.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:46.536235+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-08-27"},{"id":32370,"accession_number":"0001683168-26-006742","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"Valion Bio announced a 1-for-25 reverse stock split effective August 31, 2026, explicitly to \"bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" The company received a Nasdaq notification on March 19, 2026, that its stock price fell below $1.00 for 30 consecutive trading days, triggering a 180-day compliance period ending September 15, 2026. The reverse split directly addresses delisting risk and is material to investors assessing the company's continued exchange listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T12:31:46.536235+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-08-27"}]}